Key terms
About HRMY
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest HRMY news
May 02
3:20am ET
Harmony Biosciences Outperforms Expectations with Strong Q1 Results and Strategic Acquisition
May 01
8:01am ET
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
May 01
6:47am ET
Harmony Biosciences Holdings Sell Rating: Concerns Over Product Differentiation, Patent Litigation, and R&D Pipeline
Apr 30
8:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Decibel Cannabis Company (OtherDBCCF) and Avid Bioservices (CDMO)
Apr 30
8:03am ET
Harmony Biosciences Unveils Investor Presentation with Future Insights
Apr 30
7:40am ET
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)
Apr 30
7:07am ET
Harmony Biosciences sees FY24 net product revenue $700M-$720M
Apr 30
7:06am ET
Harmony Biosciences reports Q1 adjusted EPS 88c, consensus 62c
Apr 30
7:05am ET
Harmony Biosciences acquires Epygenix Therapeutics for $35M in cash
Apr 12
8:30am ET
Piper Sandler Remains a Buy on Harmony Biosciences Holdings (HRMY)
Apr 12
1:50am ET
Analysts Are Bullish on Top Healthcare Stocks: InMode (INMD), Resmed (RMD)
Apr 11
8:07am ET
Harmony Biosciences signs exclusive licensing agreement for sleeping disorders
Apr 09
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)
Apr 03
8:07am ET
Harmony Biosciences begins Phase 3 registrational study of pitolisant in PWS
Mar 27
4:55am ET
Harmony Biosciences management to meet with Oppenheimer
Mar 25
12:50pm ET
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)
Mar 25
8:00am ET
Harmony Biosciences management to meet with Oppenheimer
Feb 27
6:37am ET
Harmony Biosciences price target lowered to $40 from $42 at Mizuho
Feb 22
8:21am ET
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Harmony Biosciences Holdings (HRMY) and Tandem Diabetes Care (TNDM)
Feb 22
8:02am ET
Harmony Biosciences Releases Investor Presentation Update
Feb 22
7:37am ET
Harmony Biosciences reports Q4 adjusted EPS 73c, consensus 48c
Feb 21
8:07am ET
Harmony Biosciences: FDA grants priority review for sNDA for WAKIX
Feb 20
8:07am ET
Harmony Biosciences’ pitolisant designated Orphan Drug in Prader-Willi syndrome
Feb 15
6:47am ET
Harmony Biosciences price target raised to $42 from $33 at Mizuho
Feb 13
5:22am ET
Maintaining Buy Rating for Harmony Biosciences Amid Potential Competition and Market Dynamics
Feb 12
6:39pm ET
Harmony Biosciences’ treatment of PWS receives FDA orphan designation
No recent press releases are available for HRMY
HRMY Financials
Key terms
Ad Feedback
HRMY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
HRMY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
